Supportive care for patients with brain cancer and their families


Published on

  • Be the first to comment

  • Be the first to like this

Supportive care for patients with brain cancer and their families

  1. 1. Supportive care for patients with brain cancer and their families Highlights from the 9th Meeting of the European Association of Neuro- Oncology September 16-19, 2010, Maastricht, The Netherlands A diagnosis of brain cancer is very distressing to the individual and to his/her partner and relatives. In the course of the disease, many patients suffer from depression, and the disease also has a social impact on family life. A growing awareness of the need to tackle these problems in the clinical setting has led to various suggestions as to how neuro-oncology specialist nurses and physicians could offer support and psychosocial assistance to patients and their families. Diagnosing and tackling depression in patients with brain cancer Depression is a common occurrence in patients with brain cancer, and it involves emotional, cognitive, and physical sequelae. Depression appears to be associated with increased morbidity and mortality in this patient population and importantly, it is the most important independent predictor of quality of life (QoL) for patients with brain cancer. The root cause of the depression may be linked to the location of the tumour, the forms of treatment, and the patient’s response to the diagnosis. In general,
  2. 2. depression in these patients is under-diagnosed; the psychiatric symptoms can often be unrecognized or mistaken for neurological symptoms of the brain tumour. A common theme of the presentations on this topic at the EANO meeting is that patients should be evaluated for depression before, during, and after treatment of their brain cancer. Early treatment of depression might decrease the morbidity and mortality and improve the QoL of these patients. Identifying clinical depression in patients with brain tumours Dr. Alasdair Rooney (Edinburgh Centre for Neuro-oncology, Western General Hospital, Edinburgh, UK) outlined the results of a prospective, twin-centre, longitudinal cohort study to assess the frequency, course and clinical associations of major depressive disorder (MDD) in adults with glioma (O.49). MDD was diagnosed in almost 20% of the patients during the study period and it was still present at the reassessment after 3 months. Functional impairment and emotional distress were identified as independent risk factors. Dr. Rooney suggested that clinicians should screen for depression in patients with glioma who report high distress on the NCCN distress thermometer or who are functionally impaired (KPS ≤70). Although there is greater recognition of the importance of early detection of the symptoms of depression, a validated tool for screening for depression in adults
  3. 3. with glioma is lacking. In a separate presentation (O.51), Dr. Rooney suggested that the depression subscale of the hospital anxiety and depression scale (HAD-D) could be used to improve the standard of supportive and psychological care for adults with glioma. He cautioned however that the impact of cognitive impairment and the reproducibility and internal consistency of the scale remain to be studied. The supportive role of the specialist nurse The neuro-oncology specialist nurse (NOSN) plays a key role in acting as a point of contact for patients, their caregivers, and all the healthcare professionals involved in the clinical management of the patient with a brain tumour. Dr. Madelena Stauss (James Cook University Hospital, Middlesbrough, UK) reported on an assessment of the involvement of NOSNs in the management of patients with a diagnosis of high-grade malignant glioma. This study involved a retrospective review of NOSN records relating to the management of 123 patients (70 males and 43 females; mean age, 59 years) who were diagnosed with intracranial glioma of WHO grades III and IV from July 2007 to June 2009. NOSN involvement with the patients was low at the time of initial consultation but there was increased involvement in 93% of the cases during treatment. The NOSN was also in contact with caregivers and dealt with clinic scheduling, symptom management, medication/steroids, psychological support, and referral to other agencies. The NOSN also had significant contacts with other health professionals as part of the process of advancing patient care. This study underlines the key role of the NOSN, who has a very high workload, in the management of patients with malignant glioma.
  4. 4. Psychosocial counselling for patients with glioblastoma Patients with glioblastoma are confronted with serious psychosocial issues. A study to evaluate the need for psycho-social counselling as part of the treatment plan for patients with glioblastoma was described by Dr. M. Krutzen (MAASTRO Clinic, Maastricht University Medical Center, Maastricht, The Netherlands). In this study, patients who were treated for a primary glioblastoma were referred for standard counselling at the beginning of their radiotherapy. Of the 101 referred patients, 43 (42.6%) were actively followed up, whereas 58 (57%) patients did not require further psychosocial support. Problem areas that were identified during counselling included euthanasia, work-related problems, housing, children, changes in behaviour, partner issues, and problems with coping. If psychosocial counselling is integrated into the treatment plan for patients with glioblastoma, the hurdle of seeking advice would be lowered and support would be more easily accepted, and consequently, more patients would make use of follow- up counselling. Dr. Krutzen proposed that “standard counselling should be integrated into the overall treatment plan to improve the quality of life for patients and their families”.